Cylene Pharmaceuticals About UsProductsDiscovery EnginePress ReleasesCareers
A Product-focused oncology company
PRODUCT DISCOVERY ENGINE

Our proprietary Ribosomal RNA Biogenesis Inhibitor Technology (RABIT™) is generating a diverse array of small molecule therapeutics for the treatment of various types of cancers.

View PRODUCTS in the PIPELINE
More on our DISCOVERY ENGINE

LEAD CLINICAL PROGRAM
  • CX-3543 is a first-in-class Ribosomal RNA Biogenesis Inhibitor that induces apoptotic cell death in tumor cells; the compound is in early Phase II clinical trials in patients with chronic lymphocytic leukemia, and is in late Phase I trials in patients with solid tumors.

  • Daniel Von Hoff, M.D., F.A.C.P. and John Lim, Pharm.D. guide clinical trials.
© 2008 Cylene Pharmaceuticals   | Terms of Use | Privacy Policy
CONTACT SITE MAP

built@zoomedia